Artiva Biotherapeutics, Inc.

ARTV

$9.61

$-0.19 (-1.94%)

Closed

Artiva wins FDA RMAT designation for AlloNK plus rituximab in refractory RA, reports new AlloNK autoimmune data from EULAR 2026

Loading chart...

IndexN/A

Market Cap0.24B

Enterprise Value0.09B

Income$-0.02B

Sales$0.00B

EmployeesN/A

P/E-2.71

P/SN/A

P/B0.95

P/C-1.32

EV/EBITDA-1.10

EV/SalesN/A

EPS (ttm)-3.54

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.44M

Shs Outstand0.02B

Change-1.94%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jun 2304:05PMArtiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference(globenewswire.com)

Jun 806:30AMArtiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today(globenewswire.com)

May 2909:00AMThe $13 Million Company Teaching the Immune System to Hunt Cancer(prnewswire.com)

May 2808:00AMArtiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Insider Trading

View All

Insider

Type

Price

Value

Date

RA CAPITAL MANAGEMENT, L.P.

Buy

1.9K

$8.98

$17K

Jun 26, 26

RA CAPITAL MANAGEMENT, L.P.

Buy

124.9K

$8.89

$1.1M

Jun 16, 26

RA CAPITAL MANAGEMENT, L.P.

Buy

548.6K

$7.91

$4.3M

Jun 11, 26

GC Corp.

Buy

1.1M

$11.52

$12.5M

May 11, 26

Aslan Fred

Sell

3.2K

$6.00

$19K

Dec 15, 25

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

CEO: Fred AslanEmployees: 96www.artivabio.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$251.00K	$33.49M	$4.93M	$2.00M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$251.00K	$33.49M	$4.93M	$2.00M	N/A
Gross Margin	100.00%	100.00%	100.00%	100.00%	0.00%
Operating Expenses	$67.53M	$64.16M	$64.76M	$55.27M	$18.27M
Operating Income	$-67.28M	$-30.67M	$-59.83M	$-53.27M	$-18.27M
Operating Margin	-26805.58%	-91.58%	-1213.32%	-2660.94%	0.00%
Net Income	$-58.49M	$-27.70M	$-58.39M	$-71.83M	$-17.99M
Net Margin	-23303.98%	-82.69%	-1184.10%	-3587.66%	0.00%
EPS (Basic)	$-5.20	$-1.19	$-3.32	$-4.08	$-1.02
EBITDA	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A

Artiva Biotherapeutics, Inc.

Insider Trading

Discover more